Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Glenmark is the first company in India to market the innovative FDC of Indacaterol
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Subscribe To Our Newsletter & Stay Updated
